Announced details
Treatment of amyotrophic lateral sclerosis (ALS)
The company has been granted an exclusive license to practice the patent by Keio University Educational Institution.
Keio University Educational Institution. Patent owner and patent applicant. Location, representative, capital, year established and business description: Not disclosed.
U.S. patent application no. 16/328636. Notice of Allowance received. Expiration date, patent number and registration date: Not disclosed.
There is no change to the earnings forecast for the fiscal year ending December 2026.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | KP2011 (treatment for amyotrophic lateral sclerosis (ALS)) |
| Counterparty | KEIO UNIVERSITY (Keio University Educational Institution) |
| Counterparty overview | Keio University Educational Institution. Patent owner and patent applicant. Location, representative, capital, year established and business description: Not disclosed. |
| Relationship with the Company | The company has been granted an exclusive license to practice the patent by Keio University Educational Institution. |
| Applicable area | Treatment of amyotrophic lateral sclerosis (ALS) |
| Registration number and expiry date | U.S. patent application no. 16/328636. Notice of Allowance received. Expiration date, patent number and registration date: Not disclosed. |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that securing patent rights in the United States will be a beneficial milestone for the development of KP2011's business in the United States and will further advance future clinical development and activities to out-license manufacturing and marketing rights.